In the latest trading session, 0.5 million ORIC Pharmaceuticals Inc (NASDAQ:ORIC) shares changed hands as the company’s beta touched 1.20. With the company’s most recent per share price at $11.55 changing hands around $1.4 or 13.79% at last look, the market valuation stands at $815.04M. ORIC’s current price is a discount, trading about -44.16% off its 52-week high of $16.65. The share price had its 52-week low at $6.33, which suggests the last value was 45.19% up since then. When we look at ORIC Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.81 million shares, with the 3-month average coming to 518.99K.
Analysts gave the ORIC Pharmaceuticals Inc (ORIC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.08. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ORIC as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. ORIC Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.51.
ORIC Pharmaceuticals Inc (NASDAQ:ORIC) trade information
Instantly ORIC is in green as seen in intraday trades today. With action -1.11%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 43.12%, with the 5-day performance at -1.11% in the red. However, in the 30-day time frame, ORIC Pharmaceuticals Inc (NASDAQ:ORIC) is 39.83% up. Looking at the short shares, we see there were 10.52 million shares sold at short interest cover period of 17.67 days.
The consensus price target for the stock as assigned by Wall Street analysts is 20, meaning bulls need an upside of 42.25% from its recent market value. According to analyst projections, ORIC’s forecast low is 20 with 20 as the target high. To hit the forecast high, the stock’s price needs a -73.16% plunge from its current level, while the stock would need to soar -73.16% for it to hit the projected low.
ORIC Pharmaceuticals Inc (ORIC) estimates and forecasts
Data shows that the ORIC Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 18.95% over the past 6 months, a 6.12% in annual growth rate that is considerably lower than the industry average of 15.90%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -22.33%. The 2025 estimates are for ORIC Pharmaceuticals Inc earnings to increase by 5.15%, but the outlook for the next 5-year period is at -2.58% per year.
ORIC Dividends
ORIC Pharmaceuticals Inc is expected to release its next quarterly earnings report in March.
ORIC Pharmaceuticals Inc (NASDAQ:ORIC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.50% of ORIC Pharmaceuticals Inc shares while 102.22% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 112.95%. There are 102.22% institutions holding the ORIC Pharmaceuticals Inc stock share, with NEXTECH INVEST LTD. the top institutional holder. As of 2024-06-30, the company held 7.8482% of the shares, roughly 5.29 million ORIC shares worth $37.37 million.
FMR LLC holds the second largest percentage of outstanding shares, with 7.3057% or 4.92 million shares worth $34.79 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were ACAP Strategic Fund and Vanguard Total Stock Market Index Fund. With 1.92 shares estimated at $21.64 million under it, the former controlled 2.72% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.66% of the shares, roughly 1.88 shares worth around $21.19 million.
